A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)
Katsutoshi Oda(The University of Tokyo), Hiroyuki Aburatani(The University of Tokyo), Masataka Takenaka(Jikei University School of Medicine), Hideki Tokunaga(Tohoku University), Kunihiro Nishimura(National Cerebral and Cardiovascular Center), Keiko Ueda(Japan Society for the Promotion of Science), Yosuke Konno(Hokkaido University of Science), Shoji Nagao(Saitama Medical University), Aiko Ogasawara(Saitama International Medical Center), Mayuyo Mori(The University of Tokyo), Kenji Tatsuno(The University of Tokyo), Noriomi Matsumura(Kindai University), Kosuke Yoshihara(Niigata University), Kosei Hasegawa(Saitama Medical University), Akira Nishijima(The University of Tokyo), Junzo Hamanishi(Kyoto University), Sho Sato(Saitama Medical University), Takashi Aoki(Epson (United States)), Kazuyoshi Kato(Kitasato University), Mahahiro Kagabu(Iwate Medical University), Kosuke Kashiwabara(Japan Society for the Promotion of Science)
Cited by 0
Related Papers
Inferring tumour purity and stromal and immune cell admixture from expression data
|Nature Communications|2013|10.7k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
A pan-cancer proteomic perspective on The Cancer Genome Atlas
|Nature Communications|2014|641
Vegetarian Diets and Blood Pressure
|JAMA Internal Medicine|2014|524